Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569179 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies
A Phase 1 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00569179 is a Phase 1 study that was terminated before completion, run by Indiana University. The registered enrollment target is 1 participants.
The verdict
NCT00569179, a Phase 1 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
Interventions
- DEVICE CliniMACS CD34 Reagent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569179
The ClinicalTrials.gov registry entry for NCT00569179 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CliniMACS CD34 Reagent System is the first listed.
NCT00569179 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569179 about?
NCT00569179 is a clinical study titled "A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies". The purpose of this study is to determine the maximum tolerated dose of alloreactive NK cells that can be transfused following stem cell transplant.
What is the current status of trial NCT00569179?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00569179?
The interventions under investigation include: CliniMACS CD34 Reagent System (DEVICE).
Who is sponsoring clinical trial NCT00569179?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.